Available support

Britannia support – Your partner in Parkinson’s therapy

Patients who are prescribed APO-go® can receive much more than just apomorphine. Britannia offers you and your patients a dedicated Nurse Service, 24-hour technical helpline, training and educational resources, and a full suite of support materials.

Package of care

The APO-go® Package of Care is offered to all patients free of charge in the UK, and aims to help patients make the most of their medication.

More ↓

UK Package of care

The APO-go® Package of Care is offered to all patients free of charge in the UK, and aims to provide support so patients and carers can ensure they are getting the optimum benefit from their treatment with APO-go®.

Homecare delivery service

Our UK Homecare Delivery Service (not available in Scotland) is provided free of charge and includes APO-go® prescription management to ensure continuity of supply, direct delivery of APO-go® and associated disposables to your chosen address, removal and replacement of sharps bin and a dedicated APO-go® Homecare team to manage the service.

For further information on APO-go®'s Homecare Delivery Service, please talk with your Parkinson's Nurse and/or specialist or contact the APO-go® Helpline.

APO-go® support materials

We provide the following two patients and carer support materials:

  • Technical support for your APO-go® PUMP
  • Information on how to care for your skin

If you would like to receive any of these items, or for more information on the complete range of patient materials currently available, please contact the APO-go® Helpline.

Free equipment

The APO-go® UK Package of Care provides free equipment to APO-go® patients. This includes:

  • Free loan of APO-go® PUMP when using APO-go® subcutaneous infusion using PFS
  • Free provision of syringes and connectors with each order for APO-go® medication
  • Free provision of PUMP wear and accessories, including pouches, belts and preparation trays
  • Free replacement of PUMP and/or PUMP parts if damaged, faulty or lost

Please note: Every new APO-go® PUMP comes fitted with a new battery with one spare battery supplied free of charge.

APO-go® Technical Helpline 0844 880 1327 (UK)

The APO-go® Helpline is available 24 hours a day, 365 days a year, and is manned by our friendly support team. During working hours (9am - 5pm), our team is available to help with a wide range of issues and can:

  • Help answer APO-go® PUMP or PEN technical queries
  • Provide advice on a wide range of issues to patients and their carers
  • Arrange contact for your patients with one of our dedicated Nurse Advisors in APO-go®
  • Arrange delivery of APO-go® within 36 hours direct to chemist or pharmacy - emergency supply can be delivered the same day during the working week, to most geographical locations
  • Arrange APO-go® PUMP training for you, your staff and your patients/their carers

Please note that out of hours our team is only available to help with technical PUMP queries.

APO-go® Nurse Advisors

Our trained Nurse Advisors in APO-go® and Britannia Healthcare Assistants can help to enhance the management and support of your patients and their family by working with the multidisciplinary team at your hospital, as well as healthcare teams within the community. For further information please talk with your Britannia representative.


At Britannia, we endeavour to ensure that as many aspects of the needs of Parkinson’s patients and the healthcare professionals who treat them are addressed. Here we hope you will find some resources that will be useful to you and your patients.

HCP experiences of APO-go®  - Content coming soon

Healthcare professional video

Hear what healthcare professionals think about the effects and benefits of APO-go®.

Useful websites

The following websites may be useful for your patients:

Parkinson's UK


Michael J Fox Foundation

European Parkinson's Disease Association

NHS choices

  1. 1. Silverdale M. Prog Neurol Psychiatry. 2007;11(1):24-28.
  2. 2. Parkinson’s UK. Non-motor Symptoms of Parkinson’s. Available at: https://www.parkinsons.org.uk/information-and-support/non-motor-symptoms-parkinsons. Accessed November 2019.
  3. 3. Heetun ZS, Quigley EM. Parkinsonism Relat Disord. 2012;18:433-40.
  4. 4. Marrinan S, et al. Mov Disord. 2014;29(1):23-32.
  5. 5. Isaacson S, et al. Mov Disord. 2016. Published online at: DOI: 10.1002/mcd3.12350.
  6. 6. Olanow C W, Watts R K, Koller W C. Neurology. 2001;56(11):S5.
  7. 7. Varanese, et al. Parkinson’s Disease. 2010. Vol. 2010, Article ID 480260, 9 pages. DOI:10.4061/2010/480260.
  8. 8. Lundqvist C. Neuropsychiatr Dis Treat. 2007;3(3):335–348.
  9. 9. Obeso JA, et al. Neurology. 2000;55(4):S13–S20.
  10. 10. Sujith O K, Lane C. Ther Adv Neurol Disord. 2009;2(2): 105–113.
  11. 11. Xie C-L, et al. Sci Rep. 2014;4:6027. DOI: 10.1038/srep06027.
  12. 12. Rizos A, et al. Parkinsonism Relat Disord. 2014;20:1231–1235.
  13. 13. Pfeiffer RF, et al. Parkinsonism Relat Disord. 2007;13:93–100.
  14. 14. Merello M, et al. Clin Neuropharmacol. 1997;20(2):165–67.
  15. 15. Katzenschlager R, et al. Lancet Neurol. 2018;17(9):749–759.


AM IMPAKT Study interim results. Presented at International Parkinson and Movement Disorder Society. Treatment of Parkinson’s Disease: Past, Present and Future. March 2014, Miami, Florida, USA.
Antonini A, et al. Parkinsonism and Relat Disord 2009;15S:S97-S100.
Chaudhuri KR, Ondo W. Handbook of Movement Disorders, Current Medicine Group, 2009.
Deleu D, Hanssens Y, Northway MG. Drugs and Aging 2004;21(11):687–709.
Dewey et al. Arch.Neurol 2001;58(9):1385–92.
Drapier S, et al.Parkinsonism and Relat Disord 2012;18:40-44.
Hagell P, Odin P. J Neurosci Nurs 2001;33(1):21–38.
NICE Guidelines for Parkinson’s Disease: National clinical guidelines for diagnosis and management in primary and secondary care. Royal College of Physicians, published June 2006.
Pietz K, Hagell P, Odin P. J Neurol Neurosurg Psychiatry 1998;65(5):709–16.
Riederer P et al. Parkinsonism Relat Disord 2007;13(8):466–79.
Rizos A, et al. Poster presented at MDPD, Seoul, 2013.
Ruiz PJG, et al. Movement Disord 2008;23(8):1130-1136.
Silverdale M. Continuous dopaminergic stimulation in Parkinson’s disease. Progress in Neurology and Psychiatry .2007;11(1):24-28.
Stacy M. J Neural Transm 2010;117:837-846.
Stocchi F. Neurol Sci 2008;29:S383-S386.
Todd A, James C-A. Apomorphine nodules in Parkinson’s disease: Best Practice management. British Journal of Community Nursing, Clinical Review 2008;13(10):457-63.
Bhidayasiri R, Chaudhuri K R, LeWitt P, et al. Clin Neuropharm 2015;38:89–103.

Parkinson’s UK Website. https://www.parkinsons.org.uk/content/parkinsons-symptoms.